C4 News - UK - Health - Seroxat warning
channel4.com home
Text Only
E4
FilmFour.com
attheraces
4car.co.uk
T4
TV LISTINGS   COMMUNITY   SHOP   A-Z OF SITES    SEARCH
NEWS|
news


INTERNET LINKS

Department of Health

GlaxoSmithKline
submit a url

Channel 4 is not responsible for the content of third party sites.
Seroxat warning
Health



Published: 10-Jun-2003
By: Victoria Macdonald



Doctor's have been warned not to prescribe the anti-depressant drug Seroxat to under 18's.


The regulator of healthcare products has said the drug increased the risk of children having suicidal thoughts and was not effective in treating their depression.



About 8000 children are thought to be on Seroxat - they should now seek advice from their doctor.



In the end it was nine studies based on data from more than 1,000 children that persuaded the Government that Seroxat should no longer be prescribed to anybody under the age of 18.



The patient information sheet was changed two-years ago to warn about the risk of suicidal feelings in the first few weeks of taking Seroxat, but that was for adults.



Seroxat was never licensed for children although doctors have been happy to prescribe it. Last year alone, 40,000 prescriptions were written out for up to 8,000 children and adolescents.



There are now serious questions to be answered over how long the manufacturer of Seroxat, GlaxoSmithKline, had evidence that there were concerns about the drug. And whether the Department of Health's licensing body was aware that data was available on a possible link between suicidal thoughts and adolescents taking the drug.



SEROXAT - was there delay?

  • The announcement today is based on nine research reports one of which the Keller study highlighted problems with Seroxat as early as 1991.




  • GlaxoSmithKline had all the data by the end of last year.




  • But it didn't pass the information on to the Government's Medicines and Healthcare products Regulatory Agency until the 27th of May.




  • It was in turn looked at by the Committee on Safety of Medicines and a new expert working group set up to investigate drugs in the SSRI group, which includes Seroxat and Prozac.




  • Seroxat is one of GlaxoSmithKline's best-selling drugs and they maintain that it is safe for adults. But in children the combined data showed that the risk of suicidal thoughts and self-harm was two to three times greater on the drug than on a placebo.



    All doctors were informed this morning of the decision. But a safety warning was also issued that it is dangerous to suddenly stop taking the drug - people must reduce their doses slowly.



    Today's announcement will only add to disquiet over these types of anti-depressants. Last week, Professor Alastair Hay persuaded a coroner to hear evidence into whether Prozac had caused his wife Wendy to hang herself. In the end he said it may or may not have caused her to take her life.



    The new review into SSRIs will look specifically at suicide rates and withdrawal side-effects. Companies, including GlaxoSmithKline are also to be inspected to ensure they have proper systems for evaluating data and that they are not suppressing evidence.



    MORE STORIES FROM OUR SEARCH

    NHS spending risk highlighted   20% relevant

    C4 NEWS SEARCH





    SNOWMAIL
    Snowmail - sign up to our daily newsletter




    Submit your email address for Jon Snow's newsletter

    SNOW TEXT

    LATEST SHOW VIDEO

    EMAIL US

    RING TONES



    SPECIAL REPORTS
    Channel 4 News at Noon
    Channel 4 News at Noon
    Gaby Rado: 1955-2003
    Gaby Rado: 1955-2003

    BREAKING HEADLINES
    NASA launches Mars rover
    Suu Kyi 'in good spirits'
    Prisoners on the run after van hijack
    High salt levels in kids' food
    Equities seek inspiration
    Barcelona step in for Beckham
    Minogue braves rain on London beach

    C4 NEWS INFO
    Ringtones
    Watch Last Night's Show
    Snowtext
    FAQ
    Contact Us
    About Us
    About the team
    Independent Film Making Guide
    Text only version of site

    channel 4
    About C4   |   Access Advice   |   Contact Us   |   Terms and Conditions   |    Privacy  |   Mobile  |   Help